Pediatrix Medical Group reported strong first quarter 2025 results with net revenue of $458.4 million, net income of $20.7 million, and adjusted EBITDA of $49.2 million. The company raised its full-year 2025 Adjusted EBITDA outlook range to $220 million to $240 million.
Net revenue for Q1 2025 was $458.4 million, a decrease from $495.1 million in the prior-year period, primarily due to non-same unit activity.
Net income for Q1 2025 increased significantly to $20.7 million ($0.24 per diluted share) from $4.0 million ($0.05 per diluted share) in Q1 2024.
Adjusted EBITDA for Q1 2025 was $49.2 million, up from $37.2 million in the prior-year period, driven by same-unit results and practice disposition activity.
The company raised its full-year 2025 Adjusted EBITDA outlook to a range of $220 million to $240 million, reflecting strong first-quarter performance.
Pediatrix Medical Group is raising its full-year 2025 Adjusted EBITDA outlook based on strong first-quarter performance.
Analyze how earnings announcements historically affect stock price performance